CD274 and neoplasm: More specifically, FDA revised previous indications for the two ICIs, which are now limited for (1) first-line treatment in cisplatin-ineligible patients whose tumors express PD-L1 (CPS ≥ 10% for pembrolizumab and PD-L1 stained tumor-infiltrating immune cells covering ≥ 5% of the tumor area in the case of atezolizumab), (2) subjects which have disease progression during or following platinum-containing chemotherapy, or (3) patients unfit for any platinum-based chemotherapy, regardless of PD-L1 expression.